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Abstract: 
The objective of the present study is optimization of valsartan floating tablet formulation by 23 factorial design and to evaluate the optimized 
valsartan floating tablets for in vitro drug release, preclinical pharmacokinetics and also for in vitro – in vivo correlation (IVIVC). Valsartan is 
an orally active anti-hypertensive drug, majorly absorbed from stomach and upper small intestine. Formulation of sustained release floating 
tablets of valsartan is needed because of its poor oral bioavailability and short biological half-life. Valsartan floating tablets were formulated as 
per 23 factorial design and were evaluated.  
Valsartan  floating tablets prepared as per 23 factorial design were non-disintegrating in  water  and aqueous acidic (pH 1.2) and alkaline (pH 
7.4) fluids and were of good quality with regard to drug content, hardness, friability and suitable for controlled release. Formulations Fa, Fab, 
Fac and Fabc exhibited excellent floating over >12 h with a floating lag time in the range 12-40 seconds. Higher levels (20 %) of sodium 
bicarbonate gave shorter floating lag time. Valsartan release from the floating tablets prepared except formulation Fa was slow and spread over 
12 h and dependent on the composition of the tablets.  Drug release from formulation Fa was very rapid. Valsartan release from the floating 
tablets was by non-fickian diffusion mechanism in all the cases except Fa. In the case of formulation Fa that gave rapid release of drug fickian 
diffusion was the drug release mechanism. Optimization of valsartan floating tablet formulation was done taking floating lag time as the 
parameter for optimization. For optimization, floating lag time was taken as response (Y) and level of sodium bicarbonate as (X1), level of bees 
wax as (X2) and level of starch acetate as (X3).  
The polynomial equation describing the relationship between the response, Y  and the variables, X1 , X 2 and X3 based on the observed data was 
found to be Y = 8.996  - 8.596 (X1) + 2.396 (X2) – 2.431 (X1 X2) + 0.561 (X3) - 0.521 (X1 X3) + 0.396 (X2 X3) - 0.271 (X1 X2 X3). Based on 
the  polynomial equation developed, the optimized valsartan floating tablet formulation with a floating lag time of 20 seconds could be 
formulated employing sodium bicarbonate (160mg/tablet), beeswax (28mg/tablet) and starch acetate (10mg/tablet). The optimized formulation 
(Fopt) exhibited a floating time of 12-14 h with a lag time of 21 seconds fulfilling the target floating lag time set indicating validity of the 
optimization technique employed. Formulations Fopt and Fab prepared exhibited excellent floating characteristics (floating over 12 h with a lag 
time of 21 and 12seconds respectively) and good sustained release of valsartan over 12– 14h. The optimized valsartan tablets formulated at two 
strengths 80 mg/tablet and 40 mg/tablet gave slow, gradual and complete release of valsartan in 12h. Valsartan was absorbed rapidly from IR 
tablets and slowly over longer period of time from floating tablets. Based on (AUC)o
α , the relative bioavailability ( BA) of Valsartan from FTs 
was 166.0 % when compared to Valsartan IR tablets (100%). A good level A correlation (r = 0.961) was observed between percent drug released 
(in vitro) and (AUC)o
α (in vivo) 
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INTRODUCTION:  
Oral drug delivery is the most desirable and preferred 
method of administering therapeutic agents for their 
systemic effects. The high level of patient 
compliance in taking oral dosage forms is due to the 
ease of administration, patient compliance, flexibility 
in formulation and handling of these forms[1]. 
However the oral route of administration suffers with 
certain limitations such as short residence time of the 
dosage form in the g.i. tract, unpredictable gastric 
emptying, degradation of the drug due to highly 
reactive nature of g.i. contents and existence of an 
absorption window in the gastric and upper small 
intestine for several drugs. Gastric emptying is a 
complex process and makes in vivo performance of 
the drug delivery system uncertain. Formulation of 
floating drug delivery systems is a useful approach to 
avoid this variability with increased gastric retention 
time of the drug delivery system. Floating systems or 
hydrodynamically controlled systems are low-density 
systems that have sufficient buoyancy to float over 
the gastric contents and remain buoyant in the 
stomach for a prolonged period of time .While the 
system is floating on the gastric contents, the drug is 
released slowly at the desired rate from the system. 
After release of drug, the residual system is emptied 
from the stomach .This results in an increased gastric 
residence time and a better control of the fluctuation 
in plasma drug concentration [2], [3]. Several 
approaches are currently used to retain the dosage in 
the stomach. These include bioadhesive systems, 
swelling and expanding systems, floating systems 
and other delayed gastric emptying devices [4], [5]  . 
The principle of floating tablets offers a simple and 
practical approach to achieve increased residence 
time in the stomach and upper g.i. tract to enhance 
the bioavailability and to obtain controlled release. 
Floating tablets are designed based on gas generating 
principle. Design of floating tablets needs a strong 
matrix forming polymer, a gas generating agent and a 
floating enhancer such as beeswax.  
In the present study sustained release floating tablets 
of valsartan were formulated employing Cross linked 
starch-urea, a new modified starch (50 %) as matrix 
forming polymer, sodium bicarbonate as gas 
generating agent and beeswax and starch acetate as 
floating enhancers. Valsartan is an angiotensin 
receptor blocker widely prescribed for hypertension. 
It is absorbed from stomach and upper small intestine 
[6], [7]. The oral bioavailability of valsartan was 23 
%. It has a short biological half-life of 3-6 hrs [8]. 
Hence sustained release floating tablet formulation is 
needed for valsartan to enhance its oral 
bioavailability and to prolong its therapeutic effect, to 
reduce dosage frequency and to increase patient 
compliance. 
Floating tablets of valsartan were designed in the 
present study to enhance its bioavailability and to 
achieve sustained release over 12 h for b.i.d. 
administration. Sustained release of valsartan over 
12h is aimed in addition to good floating 
characteristics. Formulation of valsartan floating 
tablets was optimized [9] by 23 factorial designs. 
The objective of the present study is optimization of 
valsartan floating tablet formulation by 23 factorial 
design and to evaluate the optimized valsartan 
floating tablets for in vitro drug release, preclinical 
pharmacokinetics and also for in vitro – in vivo 
correlation (IVIVC). 
 
MATERIALS AND METHODS: 
Materials 
Valsartan was a gift sample from M/s Micro Labs 
Ltd, Pondicherry. Cross linked starch-urea was 
prepared in the laboratory. Starch acetate (50 cps), 
sodium bicarbonate, Lactose and beeswax were 
procured from commercial sources. All other 
materials used were of Pharmacopoeial grade. 
 
Methods 
Preparation of Cross linked Starch - Urea 
Polymer [10] 
Potato starch (9 parts) was dispersed in purified water 
(10 parts) to form starch slurry. Urea (1 part), 
calcium chloride (1 part) were dissolved in purified 
water (40 parts) and the solution was heated to 
boiling. While boiling, the starch slurry was added 
and mixed. Mixing while heating was continued for 
20 minutes to form cross-linked starch-urea polymer. 
The mass formed was spread on to a stainless steel 
plate and dried at 85oC for 6-8 h. The dried polymer 
was powdered and passed through mesh No. 120.  
Formulation of Floating Tablets 
Matrix tablets each containing 80 mg of valsartan 
were formulated employing Cross linked starch- urea 
(50%) as matrix forming polymer, sodium 
bicarbonate as gas generating agent and starch acetate 
and beeswax as floating enhancers.  Valsartan 
floating tablets were formulated as per 23 factorial 
design. The three factors involved in the 23 factorial 
design are sodium bicarbonate (Factor A), beeswax 
(Factor B) and starch acetate (Factor C). The two 
levels of sodium bicarbonate (Factor A) are 10 % and 
20 %, the two levels of beeswax (Factor B) are 2 % 
and 5 % and the two levels of starch acetate (Factor 
C) are 5% and 10%. Eight valsartan floating tablet 
formulations were prepared employing selected 
combinations of the levels of the three factors as per 
23 factorial design. The floating tablets were prepared 
by melting- wet granulation method as per the 
formula given in Table 1. 
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Table 1: Formulae of Valsartan Floating Tablets 
 Prepared as Per 23 Factorial Design and Optimized Formulation 
 
The required quantities of valsartan, Cross linked starch-
urea, starch acetate, lactose and sodium bicarbonate 
were thoroughly mixed in a dry mortar by following 
geometric dilution technique. Beeswax was melted in a 
dry beaker and the blend of the above mentioned 
ingredients was added to the molten beeswax and mixed 
thoroughly.  The blend was transferred to a dry mortar 
and granulated with hydro-alcoholic (1:1) solution. The 
dried granules formed were passed through mesh No. 16 
to break the aggregates. The lubricants talc and 
magnesium stearate were passed through mesh No. 60 
on to the dry granules and blended in a closed 
polyethylene bag. The tablet granules were then 
compressed into 800mg tablets on a 8-station tablet 
punching machine (Karnavathi Rimek Minipress II) to a 
hardness of 4-5 Kg/cm2.  
 
Evaluation of Tablets  
Hardness of the tablets was tested using a Monsanto 
hardness tester. Friability of the tablets was determined 
in a Roche friabilator. Disintegration time of the tablets 
was determined using a Paramount tablet disintegration 
test machine using water, 0.1N HCl and phosphate 
buffer of pH 7.4 as the test fluids. 
 
Estimation of Valsartan 
An ultraviolet (UV) spectrophotometric method based 
on the measurement of absorbance at 250 nm in 0.1N  
HCl was used for the estimation of valsartan. The 
method obeyed Beer-Lambert’s law in the concentration 
range of 0-10 μg / mL. When a standard drug solution 
was assayed repeatedly (n=6), the relative error 
(accuracy) and coefficient of variation (precision) were 
found to be 0.75% and 1.45% respectively. No 
interference from the excipients used was observed. 
 
Floating Lag Time and Floating Time 
In Vitro buoyancy was determined by measuring 
floating lag time and duration of floating. The tablets 
were placed in a 250 ml glass beaker containing 0.1N 
HCl. The time required for the tablet to rise to the 
surface and float was determined as floating lag time. 
The duration in which the tablet remains floating was 
determined as floating time. 
 
Drug Release Study 
Drug release from the floating tablets prepared was 
studied using 8-station dissolution rate test apparatus 
(Labindia, DS 8000) employing a paddle stirrer at 50 
rpm and at a temperature of 37±1⁰C. Hydrochloric acid, 
0.1 N (900 mL) was used as dissolution fluid. A 5mL 
aliquot of dissolution medium was withdrawn through a 
filter (0.45μm) at different time intervals and assayed 
spectrophotometrically by measuring absorbance at 250 
nm. All drug release experiments were conducted in 
triplicate (n=3). 
 
Ingredient  
(mg/tab) 
F (1) F (a) F (b) F (ab) F (c) F (ac) F (bc) F (abc) F 
(opt) 
Valsartan 80 80 80 80 80 80 80 80 80 
Sodium 
bicarbonate 
80 160 80 160 80 160 80 160 160 
Bees wax 16 16 40 40 16 16 40 40 28 
Starch acetate  40 40 40 40 80 80 80 80 10 
Cross linked Starch 
Urea  
400 400 400 400 400 400 400 400 400 
Lactose 164 84 140 60 124 44 100 20 102 
Talc 10 10 10 10 10 10 10 10 10 
Magnesium 
stearate 
10 10 10 10 10 10 10 10 10 
Total weight (mg) 800 800 800 800 800 800 800 800 800 
IAJPS 2017, 4 (03), 578-586                       K.P.R. Chowdary et al                    ISSN 2349-7750 
 
w w w . i a j p s . c o m  
 
Page 581 
Data Analysis 
Drug release data were analysed as per Zero order, first 
order, Higuichi[11] and Korsemeyer - Peppas[12] 
equation models to assess drug release kinetics and 
mechanism from the floating tablets prepared. 
 
Preclinical Pharmacokinteic Evaluation: 
In vivo Pharmacokinetic evaluation was done on 
optimized Valsartan Floating Tablets in comparison to 
its immediate release (IR) tablets in normal healthy 
rabbits of either sex with a view to evaluate their in vivo 
performance. 
 
In vivo study protocol: 
The following products were tested for in vivo 
pharmacokinetic evaluation 
(i) Valsartan (40mg) IR tablets and 
(ii) Optimized Valsartan FT (40mg) 
As Valsartan studied is safe and for ease of its 
determination in plasma samples by HPLC, the 
products are tested in rabbits at human doses after 
approved by IAEC. Institutional Animal Ethics 
Committee (No. CPCSEA/CH/ORG/2015-040) 
approved the protocols. The in vivo study was 
conducted as per crossover RBD (n=6) in each case. 
Healthy rabbits weighing 2.0 -2.5 Kg were used. The 
washout period was one month .After collecting the 
blank blood sample, the product in the study was 
administered orally with 10 ml of water. Blood 
samples (1.0 ml) were collected from marginal ear 
vein at different times (0.5, 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 
11and 12h) after administration. Samples were 
collected into heparinized test tubes and were 
centrifuged for 15 min at 15,000 rpm. The plasma 
samples were stored under refrigerated conditions at 
4-8oC prior to assay for drug content on the same 
day. The plasma concentrations of valsartan were 
determined by a reported HPLC method [13] after 
revalidation. 
Estimation of Pharmacokinetic Parameters: 
Assuming one compartment open model, various 
Pharmacokinetic parameters such as   Cmax, Tmax (AUC) 
(0-12h), (AUC)(0-∞), Kel t½ and Ka were estimated from the 
Plasma drug concentration data in each case. Standard 
known methods [14], [15] were used for the estimation 
of various pharmacokinetic parameters. 
RESULTS AND DISCUSSION: 
The principle of floating tablets offers a simple and 
practical approach to achieve increased residence time 
in the stomach and upper G.I. tract to enhance the 
bioavailability and to obtain controlled release. Floating 
tablets of valsartan were designed based on gas 
generating principle. The objective of the present study 
is formulation development and optimization of 
valsartan floating tablets based on gas generating 
principle.   
Matrix tablets each containing 80 mg of valsartan were 
formulated employing Cross linked starch- urea (50%) 
as matrix forming polymer, sodium bicarbonate as gas 
generating agent and starch acetate and beeswax as 
floating enhancers. Valsartan floating tablets were 
formulated as per 23 factorial design. The three factors 
involved in the 23 factorial study are sodium bicarbonate 
(Factor A), beeswax (Factor B) and starch acetate 
(Factor C). The two levels of sodium bicarbonate 
(Factor A) are 10 % and 20 %, the two levels of 
beeswax (Factor B) are 2 % and 5 % and the two levels 
of starch acetate (Factor C) are 5% and 10%. Eight 
valsartan   floating tablet formulations were prepared 
employing selected combinations of the levels of the 
three factors as per 23 factorial design. The floating 
tablets were prepared by melting- wet granulation 
method as per the formula given in Table 1. All the 
floating tablets prepared were evaluated for drug 
content, hardness, friability, disintegration time, floating 
lag time, floating time and drug release characteristics. 
The physical parameters of the floating tablets prepared 
are given in Table 2.  
  
Table 2: Physical Parameters of Valsartan Floating Tablets 
Prepared as per 23 Factorial Design and Optimized Formulation 
Formulation Hardness 
(Kg/cm2) 
Friability 
(% wt. loss) 
Drug Content 
(mg/tablet) 
Floating lag time 
(min- sec) 
Floating Time 
(h) 
F 1 4.5 0.65 79.60 12-30 >12 
F a 5.5 0.45 80.05 0-40 >12 
F b 5.0 0.58 80.25 20-40 >12 
F ab 4.5 0.30 80.15 0-12 >12 
F c 5.5 0.45 79.20 13-20 >12 
F ac 5.5 0.48 79.45 0-30 >12 
F bc 5.0 0.72 79.80 24-10 >12 
F abc 4.5 0.45 80.20 0-32 >12 
F opt 5.5 0.60 80.15 0-21 >12 
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Hardness of the tablets was in the range 4.5-5.5 
Kg/cm2.Weight loss in the friability test was in the 
range of 0.35 % – 0.72 % in all the cases. All the 
tablets prepared contained valsartan within 100±2% 
of the labelled claim.  All the floating tablets 
prepared were found to be non-disintegrating in water 
and aqueous acidic (pH 1.2) and alkaline (pH 7.4) 
fluids. As such the prepared floating tablets were of 
good quality with regard to drug content, hardness, 
friability and were suitable for controlled release.  
In the in vitro buoyancy study, the floating lag time 
of various tablets was in the range 12 seconds to 
24.17 minutes. Floating time of all the tablets 
prepared was more than 12 hours. The floating lag 
time values were subjected to ANOVA to find out the 
significance of the individual and combined effects of 
the three factors, sodium bicarbonate, beeswax and 
starch acetate on the floating characteristics of the 
tablets prepared. The results of ANOVA indicated 
that the individual effects of sodium bicarbonate 
(Factor A) and starch acetate (Factor C) and their 
combined effect (AC) on the floating lag time are 
significant (P < 0.05).Whereas the individual effect 
of bees wax (Factor B) and all other combined effects 
of the three factors involved are not significant in 
influencing floating lag time of the tablets. 
The order of increasing floating lag time observed 
with various floating tablets prepared was Fab < Fac < 
Fabc< Fa< F1 < Fc< Fb < Fbc. Formulations  Fa, Fab, Fac 
and Fabc exhibited excellent floating over 12-14 h 
with a floating lag time in the range 12-40 seconds.  
Sodium bicarbonate at 20 % strength gave less 
floating lag time than at 10 % strength.  Formulations 
Fa, Fab, Fac and Fabc are considered as the best floating 
tablets formulated based on the floating 
characteristics.  
Valsartan release from the floating tablets formulated 
was studied in 0.1 N hydrochloric acid. Drug release 
parameters of the tablets prepared are summarized in 
Table 4. Valsartan release from the floating tablets 
prepared was slow and spread over 12 - 14 h and 
depended on the composition of the tablets. The 
release data were analyzed as per zero order, first 
order, Higuchi and Korsemeyer- Peppas kinetic 
models. The correlation coefficient (r) values in the 
analysis of release data as per different kinetic 
models are given in Table 3. The drug release plots 
are shown in Figs 1 – 2.  
Drug release from all the floating tablets prepared 
was diffusion controlled as indicated by the linear 
Higuchi plots. When the release data were analyzed 
as per Korsemeyer- Peppas equation, the release 
exponent ‘n’ was found to be in the range 0.51 - 0.63 
in all the cases except formulation  Fa   indicating 
‘non-Fickian diffusion’ as the release mechanism 
from these floating tablets. In the case of formulation 
Fa, that gave rapid release of drug, the release 
exponent ‘n’ was found to be 0.10  indicating fickian 
diffusion as the drug release mechanism. 
 
Table3: Correlation Coefficient (r) values in the analysis of Release data of Floating Tablets of 
Valsartan as per various Kinetic models 
Formulation Zero  
Order 
First  
Order 
Higuchi Korsemeyer - 
Peppas 
F 1 0.9272 0.9726 0.9978 0.9955 
F a 0.492 0.9808 0.9878 0.9818 
F b 0.9582 0.9612 0.9936 0.9928 
F ab 0.9497 0.9673 0.9978 0.9978 
F c 0.9328 0.9837 0.9928 0.9879 
F ac 0.9793 0.9758 0.9810 0.9898 
F bc 0.9558 0.9873 0.9923 0.9905 
F abc 0.9570 0.9487 0.9869 0.9792 
F opt 0.9609 0.9407 0.9932 0.9964 
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Fig. 1: Drug Release Profiles of Valsartan            Fig.2: Drug Release Profiles of Valsartan Floating Tablets 
Floating Tablets Prepared (F1 , Fa, Fb, Fab)            Prepared (Fc ,Fac, Fbc,  Fabc) and optimized  formulation (Fopt) 
              
Table 4: Release Parameters of Valsartan Floating Tablets 
Prepared as per 23 Factorial Design and Optimized Formulation 
 
Formulation T50 
(h) 
Release Rate Release 
Exponent (n) 
K0  (mg/h) K1(h-1) 
F 1 3.1 8.32 0.2513 0.51 
F a 0.36 18.22 1.9455 0.10 
F b 4.6 6.79 0.1554 0.55 
F ab 3.9 7.32   0.1920 0.52 
F c 3.8 7.71 0.1812 0.57 
F ac 6.4 6.56 0.1283 0.63 
F bc 4.6 7.24 0.1505 0.61 
F abc 5.7 6.31 0.1392 0.53 
Fopt 4.5 6.88 0.1810 0.58 
 
Optimization: 
Optimization of valsartan floating tablet formulation 
was done taking floating lag time as the parameter for 
optimization. For optimization, floating lag time was 
taken as response (Y) and level of sodium 
bicarbonate as (X1), level of bees wax as (X2) and 
level of starch acetate as (X3). The polynomial 
equation describing the relationship between the 
response, Y and the variables, X1, X 2 and X3 based on 
the observed data was found to be  
 
 
 
Y = 8.996  - 8.596 (X1) + 2.396 (X2) – 2.431 (X1 
X2) + 0.561 (X3) - 0.521 (X1 X3) + 0.396 (X2 X3) - 
0.271 (X1 X2 X3). 
The magnitude of the coefficients of the variables in 
the polynomial equation indicates the relative 
strength of the variables in influencing the response 
involved. In the above polynomial equation, the 
coefficients of variables X1 (sodium bicarbonate) is 
much higher when compared to the coefficients of 
other variables. As such the results indicate that the 
floating lag time is much influenced by the sodium 
bicarbonate levels in the formulation. 
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Based on the above polynomial equation, the 
optimized valsartan floating tablet formulation with a 
floating lag time of 20 seconds or 0.33 min could be 
formulated employing sodium bicarbonate (160 
mg/tablet), beeswax (28 mg/tablet) and starch acetate 
(10 mg/tablet). To verify valsartan floating tablets 
were formulated employing the optimized levels of 
sodium bicarbonate, beeswax and starch acetate as 
per the formula given in Table 1. The optimized 
valsartan floating tablet formulation was prepared 
and evaluated for floating and drug release 
characteristics. The optimized formulation exhibited 
a floating time of 14 h with a lag time of 21 seconds 
fulfilling the target floating lag time set. This result 
also indicated validity of the optimization technique 
employed. The optimized valsartan tablets were 
formulated at two strengths 80 mg/tablet and 40 
mg/tablet. Both the optimized valsartan tablets 
formulated gave slow, gradual and complete release 
of valsartan in 12h. Floating tablets containing 40 mg 
of valsartan per tablet were used in pharmacokinetic 
studies. 
Preclinical pharmacokinetic evaluation:  
Plasma concentrations of Valsartan observed 
following the oral administration of valsartsan IR 
tablets and Floating tablets are shown in Fig: 3 
The pharmacokinetic parameters estimated are 
summarized in Table 5. The Kel and t1/2 were 0.304 h-1 
and 2.278 h respectively for Valsartan IR tablets and 
0.168 h-1 and 4.112 h respectively for Valsartan FTs. 
The t1/2 of Valsartan estimated is in good agreement 
with the reported [8] value of 3-6 h. 
Valsartan was absorbed rapidly from IR tablets with 
an absorption rate constant (Ka) of 2.00 h-1. A Cmax of 
7.5 ± 0.19 µg/ml was observed at 2h following oral 
administration of Valsartan IR tablets. Plasma 
concentration were later decreased rapidly. 
      
 
Fig. 3:  Plasma Concentration Vs. Time Profile of  
Valsartan IR and FTs in Rabbits (n=6) 
 
Table 5:  Pharmacokinetic Parameters of Valsartan IR and FTs Estimated 
 
Pharmacokinetic 
Parameter 
Valsartan (IR) 
Tablets 
Valsartan (FTS) 
Tablets 
Cmax (µg/ml) 7.5±0.19 7.0±0.09 
Tmax (h) 2.0 3.0 
Kel (h-1) 0.304 0.168 
t1/2 (h) 2.278 4.112 
AUC012 (µg.h/ml) 31.10 44.90 
AUC0α (µg.h/ml) 32.02 53.23 
Ka (h-1) 2.00 0.963 
Rel BA (%) 100 166.0 
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Fig 4: in vitro in vivo correlation of Valsartan FTs 
 Valsartan from the FTs was absorbed slowly with a 
Ka of 0.963 h-1. A Cmax of 7.0 ± 0.09µg/ml at 3 h was 
observed with FTs. The plasma drug concentrations 
were sustained within a narrow range for extended 
period of time in the case of FTs.  
Based on (AUC)oα , the relative bioavailability ( BA) 
of Valsartan from FTs was 166.0 % when compared 
to Valsartan IR tablets (100%). 
A good level A correlation (r = 0.961) was observed 
between percent drug released (in vitro) and (AUC)oα 
(in vivo) as shown in Fig 4. 
Thus, the results of pharmacokinetic studies indicated 
that Valsartan was absorbed slowly from FTs and the 
plasma drug concentrations were sustained over 
longer period of time when compared to IR tablets. 
FTs also exhibited higher bioavailability when 
compared to IR tablets. 
CONCLUSIONS: 
1.Valsartan  floating tablets prepared as per 23 
factorial design were non-disintegrating in  water  
and aqueous acidic (pH 1.2) and alkaline (pH 7.4) 
fluids and were of good quality with regard to drug 
content, hardness, friability and suitable for 
controlled release. 
2.Formulations Fa, Fab, Fac and Fabc exhibited 
excellent floating over >12 h with a floating lag time 
in the range 12-40 seconds. Higher levels (20 %) of 
sodium bicarbonate gave shorter floating lag time.   
3. Valsartan release from the floating tablets prepared 
except formulation Fa was slow and spread over 12 h 
and dependent on the composition of the tablets.  
Drug release from formulation Fa was very rapid. 
4. Valsartan release from the floating tablets was by 
non-fickian diffusion mechanism in all the cases 
except Fa. In the case of formulation Fa that gave 
rapid release of drug fickian diffusion was the drug 
release mechanism. 
5. Optimization of valsartan floating tablet 
formulation was done taking floating lag time as the 
parameter for optimization. For optimization, floating 
lag time was taken as response (Y) and level of 
sodium bicarbonate as (X1), level of bees wax as (X2) 
and level of starch acetate as (X3).  
6. The polynomial equation describing the 
relationship between the response, Y  and the 
variables, X1 , X 2 and X3 based on the observed data 
was found to be Y = 8.996  - 8.596 (X1) + 2.396 (X2) 
– 2.431 (X1 X2) + 0.561 (X3) - 0.521 (X1 X3) + 
0.396 (X2 X3) - 0.271 (X1 X2 X3). 
7. Based on the  polynomial equation developed, the 
optimized valsartan floating tablet formulation with a 
floating lag time of 20 seconds could be formulated 
employing sodium bicarbonate (160mg/tablet), 
beeswax (28mg/tablet) and starch acetate 
(10mg/tablet). 
8. The optimized formulation (Fopt) exhibited a 
floating time of 12-14 h with a lag time of 21 seconds 
fulfilling the target floating lag time set indicating 
validity of the optimization technique employed. 
9. Formulations Fopt and Fab prepared exhibited 
excellent floating characteristics (floating over 12 h 
with a lag time of 21 and 12seconds respectively) and 
good sustained release of valsartan over 12– 14h.  
10. The optimized valsartan tablets formulated at two 
strengths 80 mg/tablet and 40 mg/tablet gave slow, 
gradual and complete release of valsartan in 12h. 
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11. Valsartan was absorbed rapidly from IR tablets 
and slowly over longer period of time from floating 
tablets. 
12. Based on (AUC)oα , the relative bioavailability ( 
BA) of Valsartan from FTs was 166.0 % when 
compared to Valsartan IR tablets (100%). 
13. A good level A correlation (r = 0.961) was 
observed between percent drug released (in vitro) and 
(AUC)oα (in vivo) 
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